ST Farm partners with Fujimoto Chemical Products, acquires exclusive sales and usage rights for patented technology (Korea)

ST Pharm, a manufacturer of pharmaceutical ingredients, has recently announced that it has entered into a joint venture with its Japanese competitors Fujimoto Chemical Products and trading company Inabata & Co., Ltd. to license technology and establish a joint venture for the production of oligonucleotides (hereinafter referred to as oligos).
The two companies announced that they have signed an agreement to form a business partnership. Through this agreement, ST Pharma will have the exclusive right to sell Fujimat, Fujimoto Chemical's patented diffusion synthesis technology, in the world except for Japan until 2030.
Inabata has secured exclusive rights to use Fujimat and exclusive rights to synthesize oligos using Fujimat. Inabata will also be responsible for supplying Fujimat to ST Farm.
During the contract period, ST Farm will own the patents related to the manufacturing technology and analysis method of oligo synthesis newly developed by ST Farm.
When producing these items, the two companies will cooperate through discussions in the contract development and manufacturing organization (CDMO) business. By applying the new technology introduced by ST Farm, the liquid phase oligonucleotide synthesis method will enable the synthesis of already existing
This will enable the company to mass-produce oligos by utilizing its existing small molecule drug production facilities.
"We are currently receiving requests for joint research from two companies," he said.